CNS Biomarkers

De-risking R&D of neurodegenerative drugs by versatile biomarker utility

CNS Biomarkers

attyloid’s sFIDA technology has successful Proof of Concept through its proven de-risking application in the pre-clinical development of an Alzheimer’s therapeutic and the future exploitation as clinical biomarker assay for the further clinical R&D of this third-party asset.

On the basis of this successful validation, attyloid is seeking collaborative partners for similar de-risking sFIDA application in partner programs of clinical drug development.

CNS- Biomarkers


1 Herrmann, Y. et al. Nanoparticle standards for immuno-based quantitation of alpha-synuclein oligomers in diagnostics of Parkinson’s disease and other synucleinopathies. Clin Chim Acta 466, 152-159, doi:10.1016/j.cca.2017.01.010 (2017).

2 Herrmann, Y. et al. sFIDA automation yields sub-femtomolar limit of detection for Abeta aggregates in body fluids. Clin Biochem 50, 244-247, doi:10.1016/j.clinbiochem.2016.11.001 (2017).

3 Hulsemann, M. et al. Biofunctionalized Silica Nanoparticles: Standards in Amyloid-beta Oligomer-Based Diagnosis of Alzheimer’s Disease. J Alzheimers Dis 54, 79-88, doi:10.3233/JAD-160253 (2016).

4 Kravchenko, K. et al. Analysis of anticoagulants for blood-based quantitation of amyloid beta oligomers in the sFIDA assay. Biol Chem 398, 465-475, doi:10.1515/hsz-2016-0153 (2017).

5 Kuhbach, K. et al. Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay. Front Neurosci 10, 8, doi:10.3389/fnins.2016.00008 (2016).

6 Kulawik, A., Heise, H., Zafiu, C., Willbold, D. & Bannach, O. Advancements of the sFIDA method for oligomer-based diagnostics of neurodegenerative diseases. FEBS Lett 592, 516-534, doi:10.1002/1873-3468.12983 (2018).

7 Wang-Dietrich, L. et al. The amyloid-beta oligomer count in cerebrospinal fluid is a biomarker for Alzheimer’s disease. J Alzheimers Dis 34, 985-994, doi:10.3233/JAD-122047 (2013).